Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
Financials ($)
Sales 2018 56,1 M
EBIT 2018 -390 M
Net income 2018 -227 M
Finance 2018 255 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 52,0x
EV / Sales 2019 27,4x
Capitalization 3 176 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 84,8 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC33.23%3 219
GILEAD SCIENCES1.59%96 150
VERTEX PHARMACEUTICALS20.99%45 720
REGENERON PHARMACEUTICALS2.18%41 951
NEUROCRINE BIOSCIENCES, INC.41.84%10 366
SAREPTA THERAPEUTICS INC136.05%9 222